Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.45 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | PDE4A | P27815 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8393918 | 0.85 | F10 (0.47) | F10F2PDE4APDE4BPDE4C | |
| SCHEMBL1997406 | 0.84 | F10 (0.57) | F10F2PDE4APDE4BPDE4C | |
| SCHEMBL541689 | 0.84 | F10 (0.61) | F10F2 | |
| SCHEMBL1996121 | 0.83 | CCNA2 (0.49) | F10F2 | |
| SCHEMBL14350836 | 0.83 | PDE4A (0.49) | F10F2PDE4APDE4BPDE4C | |
| SCHEMBL1997507 | 0.83 | F10 (0.48) | F10F2PDE4APDE4BPDE4C | |
| SCHEMBL6213701 | 0.82 | PDE4A (0.44) | F10F2PDE4APDE4BPDE4C | |
| SCHEMBL1997488 | 0.81 | ALDH1A1 (0.51) | F10F2PDE4APDE4BPDE4C | |
| SCHEMBL2003019 | 0.80 | F10 (0.50) | F10F2 | |
| SCHEMBL8393902 | 0.80 | PDE4A (0.41) | F10F2PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371761-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-13 | — | — | US | claimed |
| US-20200140436-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-07 | — | — | US | disclosed |
| CN-110894196-A | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | 百时美-施贵宝控股爱尔兰无限公司 | 2020-03-20 | — | — | CN | disclosed |
| US-20180244673-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-30 | — | — | US | disclosed |
| US-9975891-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170050964-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-02-23 | — | — | US | disclosed |
| US-20150210691-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-30 | — | — | US | disclosed |
| US-20140113892-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-24 | — | — | US | disclosed |
| US-8470854-B2 | Lactam-containing compounds and derivatives thereof as factor XA inhibitors | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120201816-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-09 | — | — | US | disclosed |
| US-7005435-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-02-28 | — | — | US | disclosed |
| US-6995172-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-02-07 | — | — | US | disclosed |
| US-6989391-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS-SQUIBB PHARMA COMPANY (US) | 2006-01-24 | — | — | US | disclosed |
| US-20050267097-A1 | blood coagulation factor (trypsin-like serine protease enzymes) inhibitor; 3-(4-methoxy-phenyl)-5-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-3,5,6,7-tetrahydro-[1,2,3]triazolo4,5-c]pyridin-4-one; anticoagulant; cardiovascular thromboembolic disorder transient ischemic attack, stroke, atherosclerosis | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | disclosed |
| US-20050261287-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-24 | — | — | US | disclosed |
| US-6967208-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050171085-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-04 | — | — | US | disclosed |
| US-20050124602-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-09 | — | — | US | disclosed |
| US-20040220174-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-04 | — | — | US | disclosed |
| US-20030191115-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244673-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | F10 45/4885F2 2/4885PDE4A 1122/4885 |
| US-20120201816-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | F10 45/4885F2 2/4885PDE4A 1122/4885 |
| US-20150210691-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | F10 43/4885F2 2/4885PDE4A 1241/4885 |
| US-20050261287-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | F12, F2, CPB1 | F10 45/4885F2 2/4885PDE4A 1122/4885 |
| US-20040220174-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | PEPD, PRSS1, CPB1 | F10 43/4885F2 4/4885PDE4A 491/4885 |
| US-20170050964-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | F10 45/4885F2 2/4885PDE4A 1122/4885 |
| US-20050124602-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | F12, F2, CPB1 | F10 43/4885F2 2/4885PDE4A 1241/4885 |
| US-20050267097-A1 | blood coagulation factor (trypsin-like serine protease enzymes) inhibitor; 3-(4-methoxy-phenyl)-5-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-3,5,6,7-tetrahydro-[1,2,3]triazolo4,5-c]pyridin-4-one; anticoagulant; cardiovascular thromboembolic disorder transient ischemic attack, stroke, atherosclerosis | PLAT, F2, TFPI | F10 62/4885F2 2/4885PDE4A 2706/4885 |
| US-20050171085-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | F12, F2, CPB1 | F10 45/4885F2 2/4885PDE4A 1122/4885 |
| US-20140113892-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | F10 43/4885F2 2/4885PDE4A 1241/4885 |
| US-20200140436-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | F10 43/4885F2 2/4885PDE4A 1241/4885 |
| US-20030191115-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | PEPD, HABP2, CPB1 | F10 33/4885F2 13/4885PDE4A 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.